뒤로
Orexo AB (publ)(ORXOY) 가격
ORXOY 주가 차트
ORXOY 수입
Orexo AB (publ)
$2.6
0%
$0
종가: Jan 16, 16:00:00 GMT-5
$2.6
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-10-23
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ORXOY의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Orexo AB (publ) ORXOY의 지난 분기 매출 실적은 어땠나요?
Orexo AB (publ)의 매출 추정치는 얼마인가요?
Orexo AB (publ)의 수익 품질 점수는 얼마인가요?
Orexo AB (publ)는 언제 수익을 보고하나요?
Orexo AB (publ)의 예상 수익은 얼마인가요?
Orexo AB (publ)은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$2.6
시가
$2.6
일일 범위
$2.6 - $2.6
52주 범위
$1.47 - $4.05
거래량
100
평균 거래량
35
EPS(TTM)
-0.63
배당수익률
--
시가총액
$90.2M
Orexo AB란 무엇인가요?
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 104 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.